Silence Therapeutics Plc's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 87.86, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Silence Therapeutics Plc in Jun 30 2026 quarter, has decreased to 4 days, compared to 12 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 513 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 3322 to 3339.

What is Receivable Turnover Ratio?
What is Silence Therapeutics Plc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SLN Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	-	-	-	-90.34 %	-62.72 %
Y / Y Revenue Change	-	197.18 %	-99.87 %	-89.39 %	-70.37 %
Receivable Turnover Ratio (TTM)	87.86	29.7	14.52	91.76	78.3
SLN's Total Ranking	# 3339	# 3322	# 3078	# 70	# 182
Accounts Receivable average collection period days	4	12	25	4	5
Seq. Receivable Change	-	-	-	-67.06 %	107.32 %
Seq. Revenue Change	-	1141.18 %	-78.62 %	-29.02 %	57.75 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 168
Healthcare Sector	# 514
Overall Market	# 3339

Receivable Turnover Ratio Statistics
High	Average	Low
64.48	25.01	0.61
(Sep 30 2025)		(Dec 31 2025)

News about Silence Therapeutics Plc Receivables Turnover Ratios

Pioneering Advances in Polycythemia Vera Treatment Insights from Silence Therapeutics’ Phase 1 Study

: The treatment landscape for Polycythemia Vera (PV), a myeloproliferative neoplasm characterized by abnormal proliferation of red blood cells, is advancing with innovative therapies targeting molecular pathways involved in disease pathogenesis. Silence Therapeutics, a leader in RNA interference (RNAi) therapeutics, presented promising Phase 1 data for their novel siRNA therapy, divesiran, at the American Society of Hematology (ASH) Annual Meeting. This study targets TMPRSS6, a gene implicated in the regulation of iron homeostasis, offering a potentially transformative approach in PV management. This article delves into the Phase 1 study s findings, examining the clinical implications and future directions for divesiran in PV treatment.Polycythemia Vera (PV) is a chronic hematologic disorder characterized by an increased production of erythrocytes, often accompanied by elevated leukocytes and platelets. Current therapeutic strategies are aimed at mitigating thrombotic risks and disease-related symptoms primarily through phlebotomy, hydroxyurea, and low-dose aspirin. Nevertheless, these treatments often fall short in addressing the underlying pathophysiological mechanisms of PV. In recent years, the emergence of RNA interference (RNAi) therapies has provided a new frontier in targeted disease interventions. The SANRECO study, examining Silence Therapeutics’ siRNA agent divesiran, has showcased encouraging Phase 1 data, indicating a promising path forward in PV treatment.

SLN Company Profile • Back to SLN Efficiency Comparisons • Compare SLN Receivables Turnover Ratio to its Competitors

Financial Statements
Silence Therapeutics Plc's Accounts Receivable	$ 0 Millions	Visit SLN's Balance sheet
Silence Therapeutics Plc's Sales TTM	$ 1 Millions	Visit SLN's Income Statement
Sources of SLN's Revenues		Visit SLN's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
SLN's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
SLN's Growth Rates	SLN's Roa	SLN's Inventory Turnover Ratio	SLN's Dividend Comparisons
SLN's Profitability Ratios	SLN's Roi	SLN's Asset Turnover Ratio	SLN's Dividend Growth
SLN's Valuation Ratios	SLN's Roe	SLN's Financial Strength Ratios	SLN's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector

Receivable Turnover Ratio

Revenues for 12 Months ending Jun 30 2026

Receivable at quarter ending Jun 30 2026

Date modified: 2026-08-31T19:03:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.